Who is sponsoring NCT05134597?

NCT05134597 is sponsored by University of Catanzaro.

What drugs are being tested in NCT05134597?

Interventions in NCT05134597: Genetic assessment.

What condition does NCT05134597 study?

NCT05134597 studies Genetic Predisposition to Disease, Inflammation, Venous Leg Ulcer.

Is NCT05134597 still recruiting?

NCT05134597 is currently status unknown. Last updated 26 November 2021.

Last reviewed 2021-11-26 · How we verify

NCT05134597: GECVELUS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gene Expression in Chronic Venous Leg Ulcers

Status unknown Last updated 26 November 2021

What this trial tests

trial testing Genetic assessment in Genetic Predisposition to Disease in 30 participants. Status unknown.

Timeline

1 January 2021

Primary endpoint
31 December 2021

31 March 2022

Quick facts

Lead sponsor	University of Catanzaro
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	30
Start date	1 January 2021
Primary completion	31 December 2021
Estimated completion	31 March 2022
Sites	1 location across Italy

Drugs / interventions tested

Genetic assessment

Conditions studied

Genetic Predisposition to Disease — all drugs for Genetic Predisposition to Disease →
Inflammation — all drugs for Inflammation →
Venous Leg Ulcer — all drugs for Venous Leg Ulcer →

Sponsor

University of Catanzaro

Who can join

18 and older, any sex, with Genetic Predisposition to Disease or Inflammation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Chronic Venous Disease (CVD) is a widespread clinical condition widely spread in the western countries that may negatively impact the quality of life (QoL) of affected patients. Chronic venous leg ulcers (CVLUs) are the most severe form of CVD, and several genetic and molecular alterations have been studied in order to understand the progression of CVD towards CLVUs. Chronic inflammation is a key element in CVLUs onset, and recently T helper 17 (Th-17) cells, a subtype of pro-inflammatory T helper (CD4+) cells defined by the production of a cytokine signature of which IL-17 represents the progenitor, seem to be related to several chronic disease. The aim of this study is to evaluate Th17- Gene Expression profile in patients with CVD and CVLUs.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Th17-Gene Expression Profile in Patients with Chronic Venous Disease and Venous Ulcers: Genetic Modulations and Preliminary Clinical Evidence.
Amato R, Dattilo V, Brescia C, D'Antona L, et al · · 2022 · cited 8× · PMID 35883458 · DOI 10.3390/biom12070902

Verify or expand the search:

Other recruiting trials for Genetic Predisposition to Disease

Currently open trials in the same condition.

NCT06962059 — Healthy Volunteers Study · recruiting
NCT07018128 — Expression of Genes Relating Hypertension and Efficacy of 4-7-8 Breathing Control on Reducing Blood Pressure · NA · recruiting
NCT06399666 — Impact of Inflammatory Indexes and Gene Scores in Prediction of Atrial Fibrillation · recruiting
NCT05772559 — Acute Myeloid Leukemia At Initial Diagnosis and/or Relapse in Children, Teenagers and Young Adults: Molecular Profiling, · recruiting
NCT05759143 — Enhancing Information Management for Young Adults After Genetic Cancer Risk Testing · NA · recruiting

Other University of Catanzaro trials

Trials by the same sponsor.

NCT06844552 — Diamagnetic Therapy in Pain and Inflammation · recruiting
NCT07508969 — Proprioceptive Neuromuscular Facilitation vs Conventional Therapy With Ultrasound-Guided Corticosteroid Injections for S · Phase 1, PHASE2 · completed
NCT07504432 — Efficacy of Oxygen-ozone Therapy and Cervical Rehabilitation · Phase 1, PHASE2 · completed
NCT06814769 — Hyaluronic Acid and Articular Pain · completed
NCT04654104 — Immune Checkpoints in COPD · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05134597 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Catanzaro
Last refreshed: 26 November 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05134597.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing